Chronic Myelogenous Leukemia

• Chronic Myelogenous Leukemia (CML) is a slow-growing cancer of the blood and bone marrow.
• It is primarily caused by a specific genetic abnormality called the Philadelphia chromosome.
• Symptoms can be subtle initially, including fatigue, weight loss, and an enlarged spleen.
• Diagnosis involves blood tests and bone marrow examination to identify the Philadelphia chromosome.
• Modern treatments, particularly targeted therapies, have significantly improved the prognosis for individuals living with CML.

What is Chronic Myelogenous Leukemia (CML)?

Chronic Myelogenous Leukemia (CML) is a cancer of the blood and bone marrow that progresses slowly over time. It is characterized by the overproduction of white blood cells, specifically myeloid cells, in the bone marrow. This condition is primarily caused by a genetic mutation that occurs in a blood stem cell, leading to the formation of an abnormal gene called BCR-ABL. This abnormal gene is located on a shortened chromosome 22, known as the Philadelphia chromosome (Ph chromosome). The presence of the Philadelphia chromosome is a hallmark of CML, found in over 95% of cases (American Cancer Society).

CML Leukemia Symptoms, Causes, and Diagnosis

Understanding CML leukemia symptoms and causes is crucial for early detection and management. CML often progresses slowly, and many individuals may not experience noticeable symptoms in the early chronic phase. When symptoms do appear, they are often non-specific and can include:

• Fatigue and weakness
• Unexplained weight loss
• Fever and night sweats
• Pain or fullness below the ribs on the left side (due to an enlarged spleen)
• Easy bruising or bleeding
• Bone or joint pain

The primary cause of CML is the acquisition of the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. This genetic change is not inherited but occurs spontaneously during a person’s lifetime. The BCR-ABL gene produced by this translocation leads to the uncontrolled growth of myeloid cells.

Diagnosis of CML typically begins with a complete blood count (CBC), which may reveal an elevated white blood cell count. If CML is suspected, further tests are performed:

• Bone Marrow Aspiration and Biopsy: To examine blood-forming cells and assess the extent of the disease.
• Cytogenetic Analysis: To identify the Philadelphia chromosome in bone marrow cells.
• Fluorescence In Situ Hybridization (FISH): A more sensitive test to detect the BCR-ABL gene.
• Polymerase Chain Reaction (PCR): A highly sensitive test to measure the amount of BCR-ABL gene in blood or bone marrow, used for diagnosis and monitoring treatment response.

Chronic Myelogenous Leukemia Treatment and Prognosis

Significant advancements in Chronic Myelogenous Leukemia treatment options have transformed the outlook for patients. The primary treatment for CML is targeted therapy, specifically with tyrosine kinase inhibitors (TKIs). These drugs work by blocking the activity of the BCR-ABL protein, which is responsible for the uncontrolled growth of leukemia cells. Examples of TKIs include imatinib, nilotinib, dasatinib, and bosutinib. For most patients, TKIs are highly effective in controlling the disease and are taken orally, often for many years.

Living with CML leukemia prognosis has dramatically improved since the introduction of TKIs. Before targeted therapies, the median survival for CML was only a few years. Today, with consistent TKI treatment, many patients can live long, productive lives, with survival rates approaching those of the general population. Regular monitoring with PCR tests is essential to track the level of the BCR-ABL gene and ensure the treatment remains effective. While CML is generally not considered curable with TKIs, the goal is to achieve a deep and sustained molecular response, effectively managing the disease as a chronic condition.